scPharmaceuticals Inc. (SCPH) Financial Statements (2024 and earlier)

Company Profile

Business Address 25 BURLINGTON MALL ROAD, SUITE 203
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments76,013118,18675,278105,09572,62489,478
Cash and cash equivalents46,81471,06174,26871,81972,62489,478
Short-term investments 29,19947,1251,01033,276  
Restricted cash and investments  182182   
Receivables4,489   310479
Inventory, net of allowances, customer advances and progress billings8,8401,230    
Inventory8,8401,230    
Prepaid expense2,4362,2822,7912,6102,6191,757
Other current assets   2412194179
Other undisclosed current assets1,1601,428    
Total current assets:92,938123,30878,275107,82675,64791,893
Noncurrent Assets
Operating lease, right-of-use asset1,4015664108151,179
Property, plant and equipment58546993127164
Restricted cash and investments    182182182
Other undisclosed noncurrent assets822672831321481,516
Total noncurrent assets:1,5418877621,2221,6361,862
TOTAL ASSETS:94,479124,19579,037109,04877,28393,755
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,9026,8074,5396,4534,8303,509
Accounts payable4,0011,5185441,6661,142587
Accrued liabilities8,9015,2893,9954,7873,6882,922
Debt   9,8052,4084072,811
Other liabilities564226   
Other undisclosed current liabilities176567476460 353
Total current liabilities:13,1347,41614,8469,3215,2376,673
Noncurrent Liabilities
Long-term debt and lease obligation38,81136,7947,35417,33819,8586,826
Long-term debt, excluding current maturities38,81136,7947,35416,85818,9156,826
Liabilities, other than long-term debt5,3167,552367219823159
Other liabilities1772836721958159
Operating lease, liability1,2827 480943
Derivative instruments and hedges, liabilities3,8577,517  765 
Other undisclosed noncurrent liabilities      1,353
Total noncurrent liabilities:44,12744,3467,72117,55720,6818,338
Total liabilities:57,26151,76222,56726,87825,91815,011
Equity
Equity, attributable to parent37,21872,43356,47082,17051,36578,744
Common stock433322
Additional paid in capital318,561298,934246,166243,830180,818175,201
Accumulated other comprehensive income (loss) (1)32(1)1  
Accumulated deficit(281,346)(226,536)(189,698)(161,664)(129,455)(96,459)
Total equity:37,21872,43356,47082,17051,36578,744
TOTAL LIABILITIES AND EQUITY:94,479124,19579,037109,04877,28393,755

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues13,59347515156 
Sublease income  47515156
Cost of revenue(3,811)     
Gross profit:9,78247515156 
Operating expenses(68,989)(36,157)(25,823)(29,933)(32,905)(29,667)
Other undisclosed operating income (loss)3,811(47)(51)(51)(56) 
Operating loss:(55,396)(36,157)(25,823)(29,933)(32,905)(29,667)
Nonoperating income8,7092,6213643111,6761,656
Investment income, nonoperating5,1041,203493151,6601,712
Other nonoperating income (expense)3,6051,418315(4)16(56)
Interest and debt expense(8,123)(3,302)(2,575)(2,587)(1,767)(1,432)
Loss from continuing operations:(54,810)(36,838)(28,034)(32,209)(32,996)(29,443)
Loss before gain (loss) on sale of properties:(28,034)(32,209)(32,996)(29,443)
Net loss available to common stockholders, diluted:(54,810)(36,838)(28,034)(32,209)(32,996)(29,443)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(54,810)(36,838)(28,034)(32,209)(32,996)(29,443)
Comprehensive loss:(54,810)(36,838)(28,034)(32,209)(32,996)(29,443)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(33)33(2)1  
Comprehensive loss, net of tax, attributable to parent:(54,843)(36,805)(28,036)(32,208)(32,996)(29,443)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: